Corbus Pharmaceuticals Holdings, Inc. (CRBP): Nasdaq/NYSE listing notice — Corbus receives Nasdaq delisting notice for bid price non-compliance; hearing requested

Corbus Pharmaceuticals Holdings, Inc.

Nasdaq Staff determined to delist CRBP for failure to maintain $1.00 minimum bid price; company will request hearing to stay suspension.
Stockholders approved reverse stock split (1:4 to 1:40) on Dec 20, 2022; board to set exact ratio to potentially regain compliance.
Previous 180-day compliance period ended Jan 3, 2023 without cure; company had transferred to Nasdaq Capital Market in July 2022.
If delisted, trading liquidity, financing ability, and investor confidence could be adversely affected.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Corbus Pharmaceuticals Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 4, 2023, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s continued non-compliance with the minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Market, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company intends to

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Corbus Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-000351

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.